Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T23:25:59.874Z Has data issue: false hasContentIssue false

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021

Published online by Cambridge University Press:  22 September 2022

Daniel S. Graciaa*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
Hans P. Verkerke
Affiliation:
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Jeannette Guarner
Affiliation:
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Ana Maria Moldoveanu
Affiliation:
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
Narayanaiah Cheedarla
Affiliation:
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Connie M. Arthur
Affiliation:
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Cheryl L. Maier
Affiliation:
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Andrew Neish
Affiliation:
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
Sara C. Auld
Affiliation:
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
Angie Campbell
Affiliation:
Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia
Neel R. Gandhi
Affiliation:
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GeorgiaDepartments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia
John D. Roback
Affiliation:
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
N. Sarita Shah
Affiliation:
Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GeorgiaDepartments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia
*
Author for correspondence: Daniel S. Graciaa, MD, Woodruff Memorial Research Building, 101 Woodruff Circle, Suite 2101, Atlanta, GA 30322. E-mail: dsgraci@emory.edu

Abstract

We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.

Information

Type
Concise Communication
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - SA
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (http://creativecommons.org/licenses/by-nc-sa/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Estimated Seroprevalence of SARS-CoV-2 IgG in Spent Samples From a Clinical Laboratory by Sampling Week and Comparison With CDC Laboratory Surveillance Estimates for the Preceding Week for the State of Georgia in January–March 2021

Figure 1

Fig. 1.Estimated prevalence of SARS-CoV-2 IgG and antigenemia in spent samples from a clinical laboratory, January–March 2021. Note. RBD, receptor binding domain; N, nucleocapsid.